CSIMarket
 


Marker Therapeutics inc   (MRKR)
Other Ticker:  
 
 

MRKR's Net Cash Flow Growth by Quarter and Year

Marker Therapeutics Inc 's Net Cash Flow results by quarter and year




MRKR Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -2.36 -6.29 -5.21 -5.60
III Quarter September -0.65 -7.75 -8.52 -5.17
II Quarter June 11.72 -3.00 -7.29 -8.13
I Quarter March -5.38 -14.68 43.16 -3.65
FY   3.33 -31.72 22.14 -22.55



MRKR Net Cash Flow fourth quarter 2023 Y/Y Growth Comment
Marker Therapeutics inc in the fourth quarter 2023 recorded net cash outflow of $ -2.36 millions.

According to the results reported in the fourth quarter 2023, Marker Therapeutics Inc achieved the best Net Cash Flow growth in Major Pharmaceutical Preparations industry. While Marker Therapeutics Inc ' s Net Cash Flow no change of % ranks overall at the positon no. in the fourth quarter 2023.




MRKR Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Marker Therapeutics Inc 's fourth quarter 2023 Net Cash Flow $ -2.36 millions MRKR's Income Statement
Marker Therapeutics Inc 's fourth quarter 2022 Net Cash Flow $ -6.29 millions Quarterly MRKR's Income Statement
New: More MRKR's historic Net Cash Flow Growth >>


MRKR Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Marker Therapeutics Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MRKR's IV. Quarter Q/Q Net Cash Flow Comment
Recent accomplishment of -2.36 millions by Marker Therapeutics inc look even worse compare to the -0.65 millions net cash outflow in the third quarter.

Within Major Pharmaceutical Preparations industry Marker Therapeutics inc achieved highest sequential Net Cash Flow growth. While Marker Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MRKR's IV. Quarter Q/Q Net Cash Flow Comment
IV. Quarter 2023 results of -2.36 millions by Marker Therapeutics inc look even less good considering the net cash outflow -0.65 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Marker Therapeutics inc achieved highest sequential Net Cash Flow growth. While Marker Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Marker Therapeutics Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Cash Flow 12 Months Ending $ 3.33 $ -0.60 $ -7.70 $ -22.42 $ -31.72
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #




Cumulative Net Cash Flow growth Comment
In the Dec 31 2023 period, Marker Therapeutics Inc had cumulative twelve months Net Cash Flow of $ 3 millions compare to net cash outflow of $ -32 millions a year ago.

Marker Therapeutics inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment
In the Dec 31 2023 period, Marker Therapeutics Inc had cumulative twelve months Net Cash Flow of $ 3 millions compare to net cash outflow of $ -32 millions a year ago.

Marker Therapeutics inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Major Pharmaceutical Preparations Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
MRKR's Net Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for MRKR's Competitors
Net Cash Flow Growth for Marker Therapeutics Inc 's Suppliers
Net Cash Flow Growth for MRKR's Customers

You may also want to know
MRKR's Annual Growth Rates MRKR's Profitability Ratios MRKR's Asset Turnover Ratio MRKR's Dividend Growth
MRKR's Roe MRKR's Valuation Ratios MRKR's Financial Strength Ratios MRKR's Dividend Payout Ratio
MRKR's Roa MRKR's Inventory Turnover Ratio MRKR's Growth Rates MRKR's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Dec 31 2023
Astrazeneca Plc-5.29%$ -5.287 millions
Lipocine Inc -6.98%$ -6.984 millions
Caredx Inc -14.62%$ -14.617 millions
Sophia Genetics Sa-16.41%$ -16.406 millions
Xencor Inc-17.78%$ -17.780 millions
Kronos Bio Inc -20.78%$ -20.784 millions
Earth Science Tech Inc -21.38%$ -21.381 millions
Hookipa Pharma inc -22.19%$ -22.193 millions
Anaptysbio Inc -24.22%$ -24.222 millions
Koru Medical Systems Inc-26.57%$ -26.570 millions
Abbott Laboratories-35.07%$ -35.069 millions
Lantheus Holdings Inc -37.16%$ -37.161 millions
Alcon inc -37.78%$ -37.778 millions
Inflarx N v -38.04%$ -38.037 millions
Novartis Ag-39.41%$ -39.413 millions
Argenx se-40.00%$ -40.005 millions
Gh Research Plc-40.04%$ -40.040 millions
Bright Minds Biosciences Inc -41.15%$ -41.154 millions
Enzon Pharmaceuticals inc -42.33%$ -42.332 millions
Myriad Genetics Inc -44.65%$ -44.653 millions
Elutia inc -46.46%$ -46.456 millions
Gilead Sciences Inc -46.70%$ -46.704 millions
Koninklijke Philips Nv-49.11%$ -49.110 millions
Avidity Biosciences Inc -49.45%$ -49.449 millions
Proqr Therapeutics N v -49.46%$ -49.460 millions
Protalix Biotherapeutics inc -49.52%$ -49.523 millions
Xeris Biopharma Holdings Inc -49.99%$ -49.994 millions
Altair International Corp -52.34%$ -52.344 millions
Macrogenics Inc -55.57%$ -55.574 millions
Atricure Inc -59.98%$ -59.983 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com